|Title||Workshop on identifying opportunities for ‘big data’ in medicines development and regulatory science|
|Date||14/11/2016 - 15/11/2016|
|Location||CCT Venue Plus, London, UK|
|Summary||Rapid developments in technology have led to the generation of vast volumes of data, which have the capability to transform the way the benefit-risk of medicinal products is assessed over their entire life cycle. However, it is recognised there are multiple challenges in the exploitation of these data. These range from the fundamental need to establish methods to enable the access to, integration and analysis of heterogeneous datasets to understanding the limitations in its use. Importantly, robust and transparent mechanisms to protect patient confidentiality are key to secure patient trust. It is important for the European Medicines Agency and the European Union medicines regulatory network to gather information on the latest developments in big data from the perspective of all stakeholders in order to identity how and when the multitude of data sources may contribute to medicinal product development, authorisation and post-marketing surveillance.|
A video recording is now available.
To view use the ‘Multimedia’ tab.
- Registration by invitation only